STIM

Neuronetics, Inc.

$2.01

-7.80%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Source: Yahoo Finance
AI summary

Price & performance

1M+10.5%
3M+3.4%
YTD+68.7%
1Y-11.3%
52-week range—
Beta1.83
Full chart and returns against a benchmark

Q-Score

57/ 100

Quality against peers; 50 is the peer median.

Growth70
Risk39
Performance70
Valuation53
Profitability54
Leverage32
Sentiment72
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$149.2M+99.2%
Net income-$39M
Net margin-26.1%+32.2 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

STIMIndustryP/E—29.61P/S0.983.49EV/EBITDA—18.38P/B8.353.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report, before the open
EPS estimate$-0.11
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate